1
|
O’Neill A, Seidman J, Cavagnero K, Li F, Nakatsuji T, Cheng J, Tong Y, Do T, Cau L, Hata T, Modlin R, Gallo R. 349 Functional screening of Cutibacterium acnes isolates reveal determinants of skin inflammation. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Leahy A, Corey G, O’Neill A, Higginbotham O, Devlin C, Barry L, Cummins N, Shanahan E, Shchetkovsky D, Ryan D, O'Connor M, Galvin R. 1081 A COMPARISON OF THE ISAR TOOL AND THE CLINICAL FRAILTY SCALE TO PREDICT MORTALITY AND ED REATTENDANCE IN A COHORT OF ED ATTENDER. Age Ageing 2022. [DOI: 10.1093/ageing/afac126.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Frailty Screening is one method by which we can risk stratify older adults to urgent assessment in the Emergency Department. The ISAR (Identification of Seniors at Risk) and Rockwood Clinical Frailty Scale are two frailty screening tools. We assessed the validity of these tools at predicting adverse outcomes for older adults presenting to the Emergency Department.
Method
This was a prospective cohort study. Patients over 65 were recruited, baseline.
demographics were obtained and a research nurse assessed them using both the Clinical Frailty Scale and ISAR. Patients were assessed by telephone interviews at one month and six months. The outcome measures assessed were mortality, ED re-attendance, hospital readmission, functional decline and institutionalisation.
Results
419 patients were recruited. 53.3% (223) were male with a median age of 76 (IQR = 10). The median ISAR and CFS score was 2,5 respectively at baseline. The mortality rate was 5.4% and rate of ED re-attendance was 16.9% at one month. The relative risk of ED re-admission with an ISAR score >/= 2 more was 1.84 (1.12, 3.02) and CFS > 4 was 1.85 (1.08, 3.16). The ISAR tool >/= 2, had a sensitivity of 74.29 (95% CI = 62.44, 83.99) and specificity of 41.18 (95% CI = 35.90, 46.61) when used as a diagnostic tool for ED re-admission at one month. The CFS > 4 had a sensitivity of 71.43 (95% CI = 57.79, 82.70) and specificity of 45.23 (95% CI = 39.33, 51.23) for the same outcome.
Conclusion
The ISAR tool >/= 2 was the more sensitive at predicting ED reattendance at one month in comparison to the Clinical Frailty Scale. We would advocate using this tool in the ED setting to highlight those at greatest risk of adverse outcomes and those most likely to benefit from Comprehensive Geriatric Assessment.
Collapse
Affiliation(s)
- A Leahy
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - G Corey
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - A O’Neill
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - O Higginbotham
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - C Devlin
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - L Barry
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- School of Nursing and Midwifery , Faculty of Education and Health Sciences, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, , Limerick, Ireland
| | - N Cummins
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| | - E Shanahan
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - D Shchetkovsky
- Department of Emergency Medicine, University Hospital Limerick , Limerick, Ireland
| | - D Ryan
- Department of Emergency Medicine, University Hospital Limerick , Limerick, Ireland
| | - M O'Connor
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - R Galvin
- School of Allied Health , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
- University of Limerick , Faculty of Education and Health Sciences, Ageing Research Centre, Health Research Institute, , Limerick, Ireland
| |
Collapse
|
3
|
Lynch S, Varasteh M, Russell E, Harney J, Conkey D, Cole A, Osman S, Flannery T, Prise K, O’Neill A, McGarry C. PO-1031 Tumour volume influences local control and overall survival following Stereotactic Radiosurgery. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07482-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
De Klerk C, Du Plessis G, Fourie JJ, O’Neill A, Smit SJA, Joubert G. The eventual outcome of patients who had lower limb amputations due to peripheral vascular disease at Pelonomi Hospital, Bloemfontein. S Afr Fam Pract (2004) 2017. [DOI: 10.1080/20786190.2016.1248145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- C De Klerk
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - G Du Plessis
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - JJ Fourie
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - A O’Neill
- Faculty of Health Sciences, School of Medicine, University of the Free State, Bloemfontein, South Africa
| | - SJA Smit
- Faculty of Health Sciences, Department of Surgery, University of the Free State, Bloemfontein, South Africa
| | - G Joubert
- Faculty of Health Sciences, Department of Biostatistics, University of the Free State, Bloemfontein, South Africa
| |
Collapse
|
5
|
Gonçalves A, Santos R, O’Neill A, Escada P, Fialho G, Caria H. Caratterizzazione della mutazione SLC26A4 c.918+2T>C e report di una nuova variante potenzialmente a rischio. Acta Otorhinolaryngol Ital 2016; 36:233-8. [PMID: 27214836 PMCID: PMC4977012 DOI: 10.14639/0392-100x-889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 11/28/2015] [Indexed: 12/02/2022]
Abstract
Pendred syndrome (PS) is the second most common type of autosomal recessive syndromic hearing loss (HL). It is characterised by sensorineural HL and goiter with occasional hypothyroidism. These features are generally accompanied by malformations of the inner ear, as enlarged vestibular aqueduct (EVA). In about 50% of probands, mutations in the SLC26A4 gene are the cause of the disease. Here we report the case of a Portuguese female, aged 47, presenting with severe to profound HL and hypothyroidism. Her mother and sister, both deceased, had suffered from HL and goiter. By MRI and CT, an enlarged vestibular aqueduct and endolymphatic sac were observed. Molecular study of the patient included screening for GJB2 coding mutations and GJB6 common deletions followed by screening of all SLC26A4 exons, as well as intronic regions 8 and 14. Mutation c.918+2T>C was found for the first time in homozygosity in the intronic region 7 of the SLC26A4 gene. Whilst sequencing the control samples, a novel mutation c.821C>G was found in heterozygosity in the exon 7 of SLC26A4 gene and was predicted to be damaging. This study thus led to the finding of two novel SLC26A4 genotypes and provides new insight on the phenotypic features associated with PS.
Collapse
Affiliation(s)
- A.C. Gonçalves
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
| | - R. Santos
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
| | - A. O’Neill
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
- FCM/UNL, Department of Anatomy, Nova Medical School, New University of Lisbon, Portugal
| | - P. Escada
- ENT-CHLO, HEM, ENT Service, Centro Hospitalar de Lisboa Ocidental EPE, Egas Moniz Hospital, Portugal
| | - G. Fialho
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
| | - H. Caria
- BioISI - Biosystems & Integrative Sciences Institute, Faculty of Science of the University of Lisbon, Portugal, * Present address: UCL Ear Institute, London, United Kingdom
- ESS/IPS, School of Health, Polytechnic Institute of Setúbal, Portugal
| |
Collapse
|
6
|
Bhatt RS, Norden-Zfoni A, O’Neill A, Zurita AJ, Wu H, Prox D, Atkins MB, Heymach JV. Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Moulder SL, O’Neill A, Arteaga C, Pins M, Sparano J, Sledge G, Davidson N. Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1033 Background: Activation of EGF receptor has been associated with resistance to trastuzumab in breast cancer cell lines. EGFR tyrosine kinase inhibitors inhibit HER2 phosphorylation and synergize with trastuzumab in HER2+ cell lines that co-express EGFR. Methods: Pts with MBC and HER2 overexpression by immunohistochemistry (3+) and/or HER2 gene-amplification by FISH, 0–2 prior chemotherapy regimens for met disease, LVEF 50%, and no prior trastuzumab were treated with trastuzumab 2 mg/kg/wk and gefitinib 250- 500 mg/day until disease progression, unacceptable toxicity or withdrawal of consent. The phase I portion of the trial used a 3+3 design to determine MTD. In the phase II portion of the trial, patients were stratified based upon prior chemotherapy exposure (Group 1= no prior exposure to chemotherapy, Group 2= prior exposure to 1–2 chemotherapy regimens). Response measured using RECIST criteria. The primary endpoint was to increase proportion progression free from 50 to 65% at 6 months in Group 1 and from 50 to 70% at 3 months in Group 2. Results: Phase I: DLT (Grade 3 diarrhea) occurred in 2/3 patients treated at the 500 mg/day dose level of gefitinib in combination with weekly trastuzumab. 0/3 patients treated at the 250 mg/day dose level experienced DLT. This was considered MTD and was the dose selected for the Phase II portion of the trial. Phase II: 36 eligible pts were enrolled. Most patients were ECOG PS of 0 and had visceral organ involvement. Of the patients enrolled in Group 1, one pt achieved a CR, one PR and 7 had SD (≥ 24 weeks). Median time to progression (TTP) was 2.9 months (95% CI, 2.5–4). In Group 2 no responses were observed with a median TTP of 2.5 months (95% CI, 1.5- 2.7). Most common severe toxicities were rash (grade 3, 14%) and diarrhea (grade 3, 30%). No grade 3 cardiac toxicity was encountered. Conclusions: Trastuzumab in combination with gefitinib at doses of 250 mg/day demonstrated an acceptable toxicity profile; however, during planned interim analysis, the TTP did not meet predetermined statistical endpoints required for study continuation. These results do not support the further use of this combination and have implications for other trials using trastuzumab and EGFR TK inhibitors simultaneously. [Table: see text]
Collapse
Affiliation(s)
- S. L. Moulder
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - A. O’Neill
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - C. Arteaga
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - M. Pins
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - J. Sparano
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - G. Sledge
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - N. Davidson
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| |
Collapse
|
8
|
Kesari S, Schiff D, Doherty L, Gigas D, Batchelor T, Muzikansky A, O’Neill A, Drappatz J, Kieran M, Wen PY. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1569 Background: There is preclinical evidence that continuous low-dose chemotherapy may inhibit tumor endothelial proliferation and prevent tumor growth (Browder et al Cancer Res 2000;60:1878). Methods: We conducted a phase II study of continuous low-dose etoposide (VP-16), alternating with cyclophosphamide (CP), in combination with thalidomide (T) and celecoxib (C) in adult patients with recurrent malignant gliomas. There was no limit on the number of prior therapies. Patients received VP-16 [35 mg/m2 (maximum 100 mg) daily for 21 days] alternating with CP [2 mg/kg (maximum 100 mg/day) for 21 days]. Thalidomide was started at 200 mg daily and increased by 100 mg weekly to a maximum of 1200 mg/day, as tolerated. Celecoxib was started at 200 mg twice daily and increased to 400 mg twice daily. MRIs were performed every 6 weeks. Patients were treated until tumor progression or development of unacceptable toxicity. Serum was collected for measurement of angiogenic peptides. Results: 48 patients were enrolled (15 female, 33 male). 28 had glioblastomas (GBM); 20 had anaplastic gliomas (AG). Median age was 53 years (range 33–74); median KPS was 70 (range 60–100). Patients had average of 2.1 prior chemotherapies; 33% had 3 or more prior chemotherapies. Toxicities included neutropenia (8 G3, 8 G4), leukopenia (13 G3, 8 G4), lymphopenia (26 G3), anemia (1 G3), thrombocytopenia (1 G3); nausea (1 G3), vomiting (3 G3), constipation (5 G3; 2 G4), colitis (2 G4), rash (1 G3), dizziness (1 G3); hypoxia (1 G3), and infection (2 G3). 2 patients had DVT and 6 had pulmonary emboli. There were no treatment related deaths. Fatigue was common but usually mild. 12% of patients had PR, 59% had SD, 29% progressed at their first scan. For GBM patients, median progression-free survival (PFS) was 11 weeks, 6 month-PFS was 9% and median survival was 21 weeks. For AG patients, median PFS was 14 weeks; 6 month-PFS was 26% and median survival was 41.5 weeks. Correlation of angiogenic peptide levels and response will be reported. Conclusions: Although there were some responders this regimen did not significantly improve survival in this heavily pretreated group of patients. However, further studies combining metronomic chemotherapy with more potent angiogenesis inhibitors such as lenalidomide or VEGFR inhibitors may be warranted. [Table: see text]
Collapse
Affiliation(s)
- S. Kesari
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - D. Schiff
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - L. Doherty
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - D. Gigas
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - T. Batchelor
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - A. Muzikansky
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - A. O’Neill
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - J. Drappatz
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - M. Kieran
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| | - P. Y. Wen
- Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Charlottesville, VA; Massachusetts General Hospital, Boston, MA; Children’s Hospital, Boston, MA
| |
Collapse
|
9
|
Goldstein LJ, O’Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.512] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. J. Goldstein
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - A. O’Neill
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - J. Sparano
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - E. Perez
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - L. Shulman
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - S. Martino
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| | - N. Davidson
- Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD
| |
Collapse
|
10
|
Hill ADK, Brady MS, Coit DG, Brennan M, Aherne N, Mukherjee A, Sarkar A, Coss A, Waldron R, Egan B, Grant DC, Barry MK, Gallagher CM, Traynor O, Hyland JMP, Younis F, Farah N, Lowry S, Gilooly M, Lee M, Walsh TN, Carton E, Mulligan ED, Caldwell MTP, Rana D, Ryan B, Mahmud N, Keeling N, Tanner WA, Keane FBV, McDonald G, Reynolds JV, McLaughlin R, Kelly CJ, Kay E, Bouchier-Hayes D, O’Neill S, Conroy E, O’Neill A, O’Connell R, Delaney C, Fitzpatrick JM, Watson RWG, Rasheed AM, Chen G, Kelly C, McDowell I, Cottel D, Bouchier-Hayes DJ, Leahy A, Kavanagh EG, Kell MR, Lyons A, Saporoschet I, Rodrick ML, Mannick JA, Lederer JA, McCourt M, Wang JH, Sookhai S, Neary P, Redmond HP. Waterford surgical october club and surgical section, royal academy of medicine joint surgical symposium at: Waterford regional hospital. Ir J Med Sci 1998. [DOI: 10.1007/bf02937973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Harbourne G, Byrne PC, Webb S, Hutchinson M, Parfrey NA, McMenamin M, O’Neill A, Gaffney E, Callagy G, Crowe J, O’Keane JC, Murphy J, Waters E, Madden M, Shanahan F, O’Sullivan G, Lee G, Brennan FK, Connolly CE, Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EG, Duggan C, O’Brien D, McCann SR, Lynch M, Cotter L, Cryan B, Greer P, Fanning S. Royal Academy of Medicine in Ireland Section of Pathology. Ir J Med Sci 1997. [DOI: 10.1007/bf02944250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|